Avaluació de la relació entre FABP4, FABP5 i el risc cardiovascular en pacients amb la sindrome d'Apnea-Hipopnea duran el son (sahs)
Obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular disease and metabolic alterations. The fatty acid binding proteins (FABP) are good candidates as markers of OSA and metabolic alterations. Carotid intimae media thickness (cIMT) is a surrogate marker of subclinical...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2013 |
| País: | España |
| Institución: | Universitat Rovira i virgili (URV) |
| Repositorio: | Repositori Institucional de la Universitat Rovira i Virgili |
| OAI Identifier: | oai:urv.cat:TDX:1273 |
| Acceso en línea: | https://hdl.handle.net/20.500.11797/TDX1273 http://hdl.handle.net/10803/127631 |
| Access Level: | acceso abierto |
| Palabra clave: | 616.2 - Patologia de l'aparell respiratori 616.1 - Patologia del sistema circulatori, dels vasos sanguinis. Trastorns cardiovasculars 61 - Medicina |
| Sumario: | Obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular disease and metabolic alterations. The fatty acid binding proteins (FABP) are good candidates as markers of OSA and metabolic alterations. Carotid intimae media thickness (cIMT) is a surrogate marker of subclinical atherosclerosis. We evaluated FABP4 and FABP5 concentrations and cIMT in OSA patients and the effect of continuous positive airway pressure (CPAP) treatment. We included 125 patients with suspected OSA. After polysomnography, 107 were diagnosed with OSA and 58 with CPAP criteria. FABP4 and FABP5 levels were determined at baseline and after 8 weeks of CPAP in those receiving this therapy. cIMT was measured by ultrasonography at baseline and after 2 years of follow up in 50 patients on CPAP and 35 without CPAP. We observed that FABP4 is directly associated with OSA severity and change with CPAP in more severe OSA, while FABP5 was not associated with OSA severity and increased with CPAP. Increased cIMT was associated with the presence of OSA, but not with its severity and regressed upon CPAP. We concluded that FABP4 and FABP5 have different associations with OSA. FABP4 but not FABP5 could be considered a marker of metabolic alterations in OSA. Our study supports the efficacy of CPAP treatment in mitigating the cardiovascular risk of OSA and suggests that increased cIMT may be a further indication for CPAP. |
|---|